Lundbeck's VYEPTI Shows Promise in Migraine Patients Unresponsive to Prior CGRP Therapies
Event summary
- Lundbeck's Phase IV THRIVE trial found 60% of participants reported 'much improved' or 'very much improved' after 24 weeks of eptinezumab treatment.
- The trial targeted migraine patients who had inadequate response to prior CGRP-targeting preventive therapies.
- Eptinezumab was well tolerated with no new safety signals identified in this patient population.
- Full results will be presented at upcoming scientific congresses and published in a peer-reviewed journal.
The big picture
Lundbeck's THRIVE trial addresses a critical evidence gap in migraine treatment, particularly for patients who don't respond adequately to first-line CGRP therapies. With approximately 40-45% of patients discontinuing initial treatments due to ineffectiveness, these results could significantly impact the competitive landscape for migraine prevention therapies. The findings may also support Lundbeck's strategic positioning in the neuro-specialty space, where it aims to expand beyond its traditional focus on psychiatry and neurology.
What we're watching
- Therapeutic Sequencing
- How these results will influence treatment sequencing strategies for migraine patients who fail initial CGRP therapies.
- Market Differentiation
- Whether Lundbeck can position VYEPTI as a preferred option for treatment-resistant migraine patients.
- Regulatory Impact
- The pace at which these findings might lead to expanded labeling or reimbursement considerations.